AEON Reports Net Loss for FY25, Plans BPD Type 2b Meeting for ABP-450 in 2026, Stock Down 16.12%

AEON Biopharma reported a net loss of $39.22 million in FY25, compared to a net income of $42.01 million in the prior year. The company plans to request a BPD Type 2b meeting in 2026 to discuss the next phase of its development program for ABP-450, a biosimilar to BOTOX. AEON's stock is down 16.12% at $0.83 in the premarket.